Last reviewed · How we verify
HER2-positive salivary gland tumors
Approved treatments
- OGIVRI · MYLAN GMBH
- Herceptin · Roche
Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity. - Herceptin · Roche
HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells. - Herceptin · National Cancer Institute (NCI)
- Trastuzumab (Herceptin) · Pfizer Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- HER2-positive salivary gland tumors patent landscape — cliff calendar, originator estates, attackable patents
- HER2-positive salivary gland tumors treatment landscape brief
- HER2-positive salivary gland tumors treatment updates RSS
Frequently asked questions about HER2-positive salivary gland tumors
What drugs treat HER2-positive salivary gland tumors?
Tracked treatments include OGIVRI, Herceptin, Trastuzumab (Herceptin).
What is the treatment for HER2-positive salivary gland tumors?
Standard treatment for HER2-positive salivary gland tumors includes OGIVRI, Herceptin, Trastuzumab (Herceptin). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: HER2-positive salivary gland tumors patent cliff · HER2-positive salivary gland tumors CI report
- Treatment: OGIVRI · MYLAN GMBH
- Treatment: Herceptin · Roche
- Treatment: Herceptin · Roche
- Treatment: Herceptin · National Cancer Institute (NCI)
- Treatment: Trastuzumab (Herceptin) · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing